CYP19A1 and breast cancer: Gold standard endocrine treatments against ER+ BC consist in suppressing estrogen biosynthesis, via the administration of aromatase inhibitors, or in counteracting ERα pro-oncogenic action via the drugging of selective ERα modulators (SERMs) or downregulators (SERDs).